Navigation Links
A new scan for lung diseases
Date:10/13/2009

People with chronic lung disease and asthma could soon be offered better treatment thanks to a new type of Magnetic Resonance Imaging (MRI) scan being pioneered at The University of Nottingham.

A purpose-built MRI research unit has been established to study a range of respiratory diseases. The unit is based at the Queens Medical Centre and will allow doctors to virtually 'see inside' the lungs of patients using a new, specifically-adapted MRI scanner.

The team of scientists and clinicians are working on a new technique using a specially-treated harmless gas which the patient is given to inhale. Unlike air, this gas shows up clearly on an MRI scan, giving an exquisitely-detailed picture of the lungs, their damaged and healthy areas. The new method also shows the gas being absorbed into the bloodstream. This will give doctors a clear idea of how well or badly the different parts of the lungs are transferring life-sustaining oxygen. The scans could also be used to guide treatment or to guide surgeons performing lung reduction operations.

The diseases to be studied using the new type of scan include asthma, lung fibrosis and Chronic Obstructive Pulmonary Disease (COPD). These diseases are a major health burden: for example COPD is among the top five causes of death and disability in the UK with around a million sufferers. It is caused by inhalation of poisonous gases or particles, most commonly in smoking, although some working environments, e.g. coalmining, are also known triggers. COPD accounts for more time off work than any other illness and places a huge burden on the health service.

At present X-rays or CT scans are used to investigate lung diseases. But X-rays and CTs only show the structure of the lung and don't reveal any detail on how well the lungs are functioning. They also involve a small exposure to radiation which can limit repeat scanning.

The MRI imaging technique to be used in the trials will use a gas called Xenon 129. The Xenon is 'hyperpolarized' using lasers which make the gas particles detectable in the MR scanner. Whilst this approach has been tried previously using Helium 3, this gas is difficult to obtain and hence is unsuitable for routine clinical work. Xenon 129 is easy to obtain and thus has the potential to be used widely in the clinic.

The team of scientists and clinicians at the University has won around 3 million from a range of sources to fund the building of the tailor-made facility at the Queen's Medical Centre. It will also pay for clinical trials of the technique and to develop better hyperpolarisation equipment to supply the gas needed. A new member of staff, physicist Professor Thomas Meersman, has been appointed from Colorado State University to help lead the hyperpolarization research.

The project is being led by Professor Ian Hall in the medical school and Professor Peter Morris, Director of the Sir Peter Mansfield MRI Centre. Professor Hall said: "This research has huge implications for the treatment and monitoring of lung disease. We are very excited to be able to combine our world-renowned MRI knowledge with the clinical expertise at the Queen's Medical Centre in Nottingham to try and develop hyperpolarized xenon MRI as the diagnostic and therapeutic monitoring tool of choice for lung-related diseases in the future."


'/>"/>

Contact: Emma Rayner
emma.rayner@nottingham.ac.uk
44-011-595-15793
University of Nottingham
Source:Eurekalert

Related medicine news :

1. National Jewish Health Developing a Molecular Roadmap for Chronic Lung Diseases
2. NIH announces expansion of Rare Diseases Clinical Research Network
3. Hard to Treat Diseases (HTDS) Management Discussion
4. 30th Anniversary Edition of Mandell, Douglas, and Bennetts Principles and Practice of Infectious Diseases is More Relevant Than Ever
5. Miss Universe Organization, Global Network for Neglected Tropical Diseases Join Forces to Eliminate Neglected Tropical Diseases in the Americas
6. IOM report released on species-jumping diseases
7. Hard To Treat Diseases (HTDS) Delivers Varicella Vaccine To Guatemala
8. Prostate cancer patients on hormone therapy at increased risk for various heart diseases
9. Equity Capital Management H1N1 Vaccines and Hard to Treat Diseases (HTDS)
10. Hard To Treat Diseases (HTDS) (H1N1) Vaccine Update
11. Infectious Disease News and Infectious Diseases in Children Provide Online Reports Dedicated to Influenza A (H1N1) virus:
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Einstein Medical is ... to cover the latest news and commentary at the 2016 ASCRS/ASOA Symposium and Congress, ... the American Society of Cataract and Refractive Surgery and the American Society of Ophthalmic ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... offer patients with non-valvular atrial fibrillation (A-Fib) an alternative to long-term warfarin medication ... offering the procedure in April of 2015, Florida Hospital Pepin Heart Institute doctors ...
(Date:5/5/2016)... ... 05, 2016 , ... TLC Laser Eye Centers announced today that it has ... will now be called “Gordon Schanzlin New Vision Institute, a TLC Laser Eye Center.” ... facility to ensure that patients continue to receive the highest quality of care. In ...
(Date:5/5/2016)... ... ... weekend, from Friday, May 6 - Sunday, May 8, fifteen elite athletes from Team ... Fi Mountain Bike Camp, hosted in conjunction with WTB and Cannondale ... Moeschler, who’ll share pro tips with the injured veterans as they rip down some of ...
(Date:5/5/2016)... SAN FRANCISCO (PRWEB) , ... May 05, 2016 ... ... in the Unites States to promise successful results with IVF and with egg ... Designed to deliver the most patient-centric and highest quality fertility care, Spring Fertility ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 5, 2016  Endo International plc (NASDAQ: ... Brian Lortie , President, U.S. Branded Pharmaceuticals, ... upon the appointment of a successor. Mr. Lortie ... Pharmaceuticals business with responsibility for all strategic, commercial ... and portfolio development, commercial operations, managed markets, manufacturing, ...
(Date:5/5/2016)... Endo International plc (NASDAQ: ENDP ) (TSX: ENL) ... former president of Allergan, Inc. and current CEO of Chase ... of TPG Capital, to its Board of Directors. The appointments ... "Endo recently embarked on a search for new Board members ... Doug and Todd are experienced leaders, and we are extremely ...
(Date:5/5/2016)... First quarter 2016 adjusted diluted earnings per share (EPS) ... First quarter reported diluted (GAAP) loss per share from ... 2016 financial guidance; now expects 2016 revenues to range from ... earnings per share to range from $4.50 to $4.80 ... manufacturing facility restructuring , Company expands Board ...
Breaking Medicine Technology: